Cancer HorizonsAll NewsBlogsCaregivingDiet and ExerciseFinancialPsychosocialRecipesSexual HealthSide EffectSponsoredSurvivorship
All VideosCURE ConnectionsCURE Expert Connections®CURE Speaking OutCURE TVEducated Patient Sound BitesOn Demand: Webinars
Conference Coverage Conference Listing
CURE AdventuresCURE AwardsEducated Patient In Person EducationEducated Patient Virtual Education
Advocacy GroupsArt GalleryClinical Trial CornerHeal®PartnersPodcastsPublicationsShare Your Story
Subscribe
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
Immunotherapy
LeukemiaLeukemiaLeukemia
Lung CancerLung Cancer
LymphomaLymphomaLymphomaLymphomaLymphoma
Myeloma
Rare CancersRare CancersRare CancersRare Cancers
Sarcoma
Skin CancerSkin Cancer
Thyroid Cancer
Spotlight -
  • Blogs
  • Breast Cancer Webinar Series
  • Cancer Horizons
  • Clinical Trial Corner
  • Heal®
  • Publications
  • Videos
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
Immunotherapy
LeukemiaLeukemiaLeukemia
Lung CancerLung Cancer
LymphomaLymphomaLymphomaLymphomaLymphoma
Myeloma
Rare CancersRare CancersRare CancersRare Cancers
Sarcoma
Skin CancerSkin Cancer
Thyroid Cancer
    • Subscribe
Advertisement

Article

January 28, 2022

Skin-Related Side Effects From a Certain Cancer Treatment May Indicate Stronger Responses, Survival

Author(s):

Darlene Dobkowski, MA

Side effects from cancer treatment with immunotherapy, which may include vitiligo and certain rashes, may point to who will respond better to the treatment, although more research is needed to determine how much weight to put on these data.

Patients who develop skin-related side effects as a result of immune checkpoint inhibitors may have a stronger response to the cancer treatment and may indicate a survival benefit compared with those who did not develop these side effects, according to findings from a recent study.

Although this benefit was particularly accentuated in patients with melanoma, it was also evident in patients with malignant neoplasms of digestive organs, urinary tract and either the bronchus or lung.

“The implications of (these) data suggest that cutaneous (or skin-related) toxicities may be favorable in the setting of immunotherapy,” said Dr. Yevgeniy R. Semenov, an instructor of dermatology at Massachusetts General Hospital and Harvard Medical School in Boston, in an interview with CURE®. “While they may be burdensome to the patients, the glass is not half empty here necessarily. There may be a silver lining on the other side of having developed them.”

Use of Immune Checkpoint Inhibitors

There has been a substantial increase in the use of immune checkpoint inhibitors to treat advanced cancers including melanoma to breast cancer, Semenov explained, with up to 250,000 patients eligible for this therapy in the United States per year.

“Despite their survival benefits, these medications have significant immune-related toxicities that contribute to morbidity and, in some cases, can contribute to mortality as well,” Semenov said. “It’s a two-edge sword, where the medication is great, but then the toxicity really needs to be understood and managed appropriately without impacting the benefit of the medication itself.”

Semenov added that skin-related side effects are the most common in patients treated with immunotherapies and often occur early in the setting of immunotherapy.

“(This) provides a very unique opportunity for us to decide is the immunotherapy working or not, or is the harm outweighing the good at a very early stage of therapy,” he said.

To examine the potential implications of skin-related side effects on survival outcomes, Semenov and his colleagues analyzed data from 7,008 patients who were treated with immune checkpoints inhibitors for malignant neoplasms of melanoma, bronchus/lung, digestive organs or the urinary tract. Of note, all patients in this study developed skin-related side effects because of their treatment. These patients were matched with 7,008 patients with cancer who did not develop skin-related side effects.

Results from the study demonstrated that development of skin toxicities as a group resulted in a 20% survival benefit among immunotherapy recipients. Several types of skin-related side effects were significantly protective from mortality including psoriasis, lichen planus/lichenoid dermatitis (an inflammatory condition of the skin), itch in the absence of rash, as well as a broad category of non-specific rashes. Several other skin-related side effects demonstrated strong clinical effects such as vitiligo (when skin loses pigment cells in blotches), Grover disease (a skin disorder with small, raised lesions on the chest and back) and bullous pemphigoid (a skin condition with large blisters on areas of the body that flex often such as the upper thighs and lower abdomen), but did not reach statistical significance.

“We found that toxicity morphology may be important,” Semenov said. “Not all cutaneous toxicities are equal. We found that patients who develop toxicities that resemble lichen planus, which is an inflammatory disease of the skin; toxicities that resemble vitiligo, which is a depigmenting disease of the skin; as well as toxicities that resemble psoriasis actually tend to have better survival outcomes than other toxicities like mucositis (inflammation and soreness of the mouth or gut), for example. The type of rash you get is important, and why that's the case is still to be fully elucidated.”

Additional Research Needed

Semenov hypothesized that the reason that some of these side effects have a favorable association with survival compared with others may have to do with the management of the side effects, which sometimes require systemic immunosuppression which may restrain the anti-tumor effect of immunotherapy. For example, vitiligo is not often treated with systemic immunosuppression, which allows the patient to “get the benefit of the immunotherapy without a decrease in the immunotherapy efficacy from taking an immunosuppressant medication to treat the skin toxicity,” he said. In contrast, side effects like bullous pemphigoid are more burdensome to the patient due to extreme itchiness and extent of rash, which typically require use of systemic immunosuppressant medications and may even lead to holding or even discontinuing the immunotherapy.

Although these findings are “very encouraging,” according to Semenov, several questions remain both for patients and clinicians.

“What do we do once a severe toxicity develops? Should we stop the immunotherapy, or do we view this as a really favorable prognostic marker that actually tells us, ‘Hey, keep going, we’re doing well,’” Semenov added. “We need to find a way to effectively treat these (skin-related side effects) while continuing with the immunotherapy. On the converse, if we don’t get any toxicity at all, is that an early sign that the medication is not as effective against the cancer? Should we be considering a stronger treatment regimen? These are all very important questions for both patients and clinicians, but it’s too early to tell how much weight to put on these data.”

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of Dr. Boffa.
Most patients in accredited hospitals had smoking discussions documented, showing key care opportunities and smoking’s impact on treatment outcomes.
Image of Dr. Reznick
Image of Kumar.
Image of Dr. Uboha.
Image of Dr. Kumar.
Image of a woman wearing a headband and glasses
Dr. Valerie Lee discussed emerging targeted therapies and personalized medicine approaches that are showing promise for those with gastrointestinal cancer.
There are a number of reasons why patients with cancer are encouraged to enroll in clinical trials, Dr. Michael J. Pishvaian explained.
Image of woman.
Related Content
Advertisement
Lung cancer remains the leading cause of cancer-related deaths in the U.S.
May 7th 2025

Breaking Barriers: Why Increasing Lung Screening is Critical

Lung Cancer Initiative (LCI)
Lung cancer remains the leading cause of cancer-related deaths in the U.S.
cancer horizons podcast logo: a white microphone on a blue background
March 4th 2024

Cannabis Talks During Cancer, Cardiometabolic Comorbidities and Current Research

Alex Biese Brielle Benyon
In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.
Dr. Suresh S. Ramalingam explains that patients with stage 3 lung cancer who undergo chemotherapy and radiation may develop radiation pneumonitis.
May 7th 2025

Managing Lung Inflammation After Chemoradiation and Tagrisso

Dr. Suresh S. Ramalingam
Dr. Suresh S. Ramalingam explains that patients with stage 3 lung cancer who undergo chemotherapy and radiation may develop radiation pneumonitis.
CURE Cancer Horizons logo
February 26th 2024

FDA Approvals from February 2024

Alex Biese Brielle Benyon
February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.
Lungs.
May 7th 2025

How Quitting Smoking After a Cancer Diagnosis Can Boost Survival

Ryan Scott
Dr. Daniel J. Boffa discusses the link between smoking cessation and increase in survival for people who are active smokers and diagnosed with cancer.
The first patient was dosed in the SKYBRIDGE study assessing peluntamig with Tecentriq for various cancers: © stock.adobe.com.
May 6th 2025

First Patient With Advanced Lung Cancer Dosed With Peluntamig Combo

Spencer Feldman
The first patient was dosed in the SKYBRIDGE study assessing peluntamig with Tecentriq for advanced small cell lung cancer and neuroendocrine carcinomas.
Related Content
Advertisement
Lung cancer remains the leading cause of cancer-related deaths in the U.S.
May 7th 2025

Breaking Barriers: Why Increasing Lung Screening is Critical

Lung Cancer Initiative (LCI)
Lung cancer remains the leading cause of cancer-related deaths in the U.S.
cancer horizons podcast logo: a white microphone on a blue background
March 4th 2024

Cannabis Talks During Cancer, Cardiometabolic Comorbidities and Current Research

Alex Biese Brielle Benyon
In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.
Dr. Suresh S. Ramalingam explains that patients with stage 3 lung cancer who undergo chemotherapy and radiation may develop radiation pneumonitis.
May 7th 2025

Managing Lung Inflammation After Chemoradiation and Tagrisso

Dr. Suresh S. Ramalingam
Dr. Suresh S. Ramalingam explains that patients with stage 3 lung cancer who undergo chemotherapy and radiation may develop radiation pneumonitis.
CURE Cancer Horizons logo
February 26th 2024

FDA Approvals from February 2024

Alex Biese Brielle Benyon
February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.
Lungs.
May 7th 2025

How Quitting Smoking After a Cancer Diagnosis Can Boost Survival

Ryan Scott
Dr. Daniel J. Boffa discusses the link between smoking cessation and increase in survival for people who are active smokers and diagnosed with cancer.
The first patient was dosed in the SKYBRIDGE study assessing peluntamig with Tecentriq for various cancers: © stock.adobe.com.
May 6th 2025

First Patient With Advanced Lung Cancer Dosed With Peluntamig Combo

Spencer Feldman
The first patient was dosed in the SKYBRIDGE study assessing peluntamig with Tecentriq for advanced small cell lung cancer and neuroendocrine carcinomas.
About Us
Advertise / Support
Editorial Board
Contact Us
CancerNetwork.com
TargetedOnc.com
OncLive.com
OncNursingNews.com
Terms & Conditions
Privacy
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.